Molecular NeuroImaging
Molecular NeuroImaging is a privately held New Haven-based biotechnology firm founded in 1998, providing specialized neuroimaging and radiopharmaceutical services to pharmaceutical and biotech sponsors across preclinical and clinical drug development programs.
- Company typePrivate
- Founded1998
- HeadquartersNew Haven, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Molecular NeuroImaging does
Molecular NeuroImaging (MNI) is a privately held biotechnology firm founded in 1998 and headquartered in New Haven, Connecticut, providing specialized neuroimaging services to the pharmaceutical and biotechnology industries. The company operates in the clinical imaging and radiopharmaceutical research services space, serving as an imaging-focused partner for drug development programs.
The operational profile described in available source material aligns MNI with the broader Perceptive platform — a multi-division provider of preclinical imaging, clinical trial imaging, and randomization and trial supply management (RTSM) services. Core offerings include an Imaging Core Lab for centralized multi-center trial imaging management, preclinical imaging services with in-house imaging centers, radiochemistry and tracer management capabilities, biodistribution and radioligand binding assay services, and proprietary preclinical imaging analysis software (VivoQuant). Supporting technology includes Interactive Response Technology (IRT/RTSM) for trial randomization and supply management, electronic Clinical Outcome Assessment (eCOA), and a Clinical Intelligence data analytics platform. Therapeutic area coverage spans CNS, oncology, hematology, obesity/weight loss, radiopharmaceutical therapy/theranostics, and rare diseases.
The company generates revenue through project-based professional services contracts with pharmaceutical and biotechnology sponsors, supplemented by managed services from IRT/RTSM engagements. Customer segments include global bio-pharmaceutical enterprises, mid-cap and startup biotechnology companies, and CROs requiring specialized imaging subcontracting. Go-to-market is direct enterprise sales with account management, supported by content marketing, conference participation, webinars, and case-study publications. Cumulative operating metrics cited include 11,000+ trials implemented, 800+ regulatory approvals supported, and 3,000+ preclinical studies. Note: the explicit corporate relationship between MNI and Perceptive is not documented in the source material.
Molecular NeuroImaging firmographics
Firmographics- Name
- Molecular NeuroImaging
- Legal name
- Perceptive
- Website
- https://mnimaging.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Molecular NeuroImaging is a privately held New Haven-based biotechnology firm founded in 1998, providing specialized neuroimaging and radiopharmaceutical services to pharmaceutical and biotech sponsors across preclinical and clinical drug development programs.
- Ownership category
- akta.pro rank
Molecular NeuroImaging industry classification
Industry- Product category
- Neuroimaging Services
- NAICS
- Scientific Research and Development Services (5417), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where Molecular NeuroImaging is headquartered
LocationHeadquarters
- HQ city
- New Haven
- HQ country
- United States
- HQ region
- North America
Markets served
Molecular NeuroImaging business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Clinical Imaging Services: Provides imaging core lab services for clinical trials including CNS, oncology, hematology, and radiopharmaceutical therapy imaging. Revenue is generated through project-based service contracts with pharmaceutical sponsors.
- Preclinical Imaging Services: Preclinical imaging services for drug discovery and development, including in-house imaging centers and radiochemistry services.
- IRT/RTSM Services: Interactive Response Technology and Randomization/Trial Supply Management services for clinical trial supply chain optimization.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Molecular NeuroImaging product offering
Product offeringCore offering
Molecular NeuroImaging is a biotechnology firm providing neuroimaging services to support brain research and clinical studies. The company operates imaging infrastructure used by research sponsors for molecular and PET-based brain imaging investigations. Its services are delivered on a project basis to pharmaceutical and academic research clients.
Product overview
Perceptive is a provider of preclinical imaging, clinical trial imaging, and randomization and trial supply management (RTSM) services. The portfolio includes Imaging Core Lab and In-House Clinical and Imaging Centers for clinical imaging, Preclinical Imaging and Radiochemistry services for discovery-phase research, and IRT/RTSM for trial logistics. Supporting software includes VivoQuant™ for preclinical image analysis. The offering is structured as a multi-service platform spanning Discovery, eClinical, and Imaging divisions.
Differentiator
Problem solved
Functional benefit
Products and services
- Neuroimaging Services Molecular and PET-based neuroimaging services for brain research studies, delivered to pharmaceutical and academic research sponsors on a project basis.
Quantifiable outcome
- 11,000+ clinical trials implemented
- +3 more outcomes
Companies that use Molecular NeuroImaging
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles1 record
Molecular NeuroImaging technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Molecular NeuroImaging partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor.
- ProTrialsminorProTrials, a contract research organization, partners with Perceptive for eClinical solutions. Perceptive provides scientific, medical, and clinical expertise honed over 30 years of delivering reliable eClinical solutions to benefit ProTrials' customers.
- ClinChoiceminorClinChoice, a global biometrics and clinical research organization, chose to partner with Perceptive due to their tenured scientific, medical, and technical teams who possess depth and diversity of experience in providing reliable data outcomes.
- ArriVentminorArriVent, a biotech company, partnered with Perceptive for deep technical expertise in tumor response criteria, imaging modalities, image collection logistics, data management, and regulatory requirements. Perceptive provided invaluable advice during protocol and charter development.
- Veralox TherapeuticsminorVeralox Therapeutics, a small biotech company, partnered with Perceptive's Medical Imaging team as incredible collaborators to advance their lead program. Perceptive worked on tight timelines to help meet study start initiation goals.
- LG ChemminorLG Chem, a pharmaceutical company, relied heavily on Perceptive's IRT expertise for overcoming challenges in complex gout trials. Perceptive's recommendations resulted in RTSM solutions that perfectly met the study needs.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Molecular NeuroImaging competitors and assessment
Company assessmentBroad incumbents
- ICON plc: Global CRO with significant imaging capabilities following the PRA Health Sciences acquisition. Provides competing imaging core lab and central nervous system trial services as part of its broader portfolio.
- Parexel: Global CRO with imaging and clinical operations across CNS, oncology, and rare diseases. Broader-portfolio competitor that can offer imaging as part of full-service study execution.
- Medpace: Mid-to-large full-service CRO with imaging and central reading capabilities. Overlapping in oncology and CNS clinical trials where MNI also operates.
- IQVIA: Global full-service CRO with imaging capabilities embedded in its broader clinical operations. Larger competitor offering sponsors bundled CRO + imaging solutions, putting pricing pressure on standalone imaging specialists.
Direct peers
- Calyx: Imaging CRO and parent group of Perceptive, offering eClinical and imaging services to pharma. Highly relevant given likely affiliation; MNI may operate within or alongside the Calyx/Perceptive ecosystem.
- Clario: Imaging CRO formed from the merger of Bioclinica and ERT, providing clinical trial imaging, eCOA, and RTSM services. Closest large-scale competitor offering an overlapping neuroscience and oncology imaging portfolio.
- WorldCare Clinical: Imaging core lab for clinical trials with strong CNS and oncology imaging expertise. Direct competitor for multi-site imaging endpoint management in pharma-sponsored studies.
- Imaging Endpoints: Imaging core lab focused on oncology and CNS clinical trials, with deep radiologist network and proprietary image analysis workflows. Direct competitor in regulatory-grade imaging core lab services.
- Invicro: Imaging CRO specializing in preclinical and clinical imaging analysis for pharma trials, with similar PET/MRI expertise and software-driven imaging biomarker work. Direct competitor in the imaging core lab space.
Emerging players
- Celerion: Early-phase clinical and bioanalytical CRO with growing imaging and radioligand binding capabilities. Partial overlap with MNI's preclinical imaging and biodistribution business.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Molecular NeuroImaging social profiles
Digital presenceMolecular NeuroImaging financial estimates
Financial estimateRevenue estimate
Valuation estimate
Molecular NeuroImaging leadership team
Management profileNumber of profiles
Molecular NeuroImaging funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Molecular NeuroImaging M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Molecular NeuroImaging
What does Molecular NeuroImaging do?
Molecular NeuroImaging is a biotechnology firm providing neuroimaging services to support brain research and clinical studies. The company operates imaging infrastructure used by research sponsors for molecular and PET-based brain imaging investigations. Its services are delivered on a project basis to pharmaceutical and academic research clients.
Is Molecular NeuroImaging a public or private company?
Molecular NeuroImaging is a private company. It is classified as unknown and is currently operating.
When was Molecular NeuroImaging founded?
Molecular NeuroImaging was founded in 1998. It employs 101 to 250 people.
Where is Molecular NeuroImaging based?
Molecular NeuroImaging is headquartered in New Haven, United States, in the North America region.
How does Molecular NeuroImaging make money?
Three revenue lines are on record. Clinical Imaging Services are the primary driver. The others are preclinical Imaging Services and IRT/RTSM Services.
Who are Molecular NeuroImaging's main competitors?
Broad incumbents on record are ICON plc, Parexel, Medpace and IQVIA. Direct peers are Calyx, Clario, WorldCare Clinical, Imaging Endpoints and Invicro. Celerion is listed as an emerging player.
Does Molecular NeuroImaging have an API?
No public API is recorded for Molecular NeuroImaging.
What industry is Molecular NeuroImaging in?
Molecular NeuroImaging's product category is Neuroimaging Services. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 5417 and its SIC code is 8731.